Tom Babich
Head of Capital Markets
New York Office | tom.babich@torreya.com | 212.257.5811
Tom Babich, Head of Capital Markets at Torreya, leads funding transactions in the United States, including private equity investments, debt placements and royalty monetizations. He also has experience working on asset divestitures, mergers, and company sales.
Notable transactions on which Tom has worked include the Credit Facility for Mid-Atlantic, equity recap of Crown Labs, monetization of Bendeka for SciDose and the sale of Topix Pharmaceuticals to New Mountain Capital.
Tom joined Torreya in 2009. Previously, he was a professional baseball player.
He received a B.A. in economics from Harvard University.
Tom is a director of Noria Therapeutics and is active with New York Cares and the Xaverian Brothers Alumni Association.
Selected Transactions
|
| Debt financing by |
|
|
$57.5 million
February 2020
|
|
| Financing with |
|
|
$40 Million
March 2019
|
|
| Credit facility from |
|
|
$70 million
January 2019
|
|
| Term loan from |
|
|
$40 Million
June 2018
|
|
| Sale of majority equity stake to |
|
|
Undisclosed
December 2017
|
|
| Co-advisor on direct public offering |
|
|
$15 million
August 2020
|
|
| Investment by |
|
|
Undisclosed
January 2020
|
|
| Growth financing with |
|
|
Undisclosed
June 2019
|
|
| Venture debt raise with |
|
|
$20 million
April 2019
|
|
| Debt recapitalization and acquisition of NextWave Pharmaceuticals from |
|
|
$125 million
September 2018
|
|
| Debt financing for acquisition of Icon Biosciences from |
|
|
$20 Million
March 2018
|
|
| Majority recap by |
|
|
Undisclosed
March 2018
|
|
| Sale to |
|
|
Undisclosed
January 2018
|
|
| Loan agreement with |
|
|
$15 Million
January 2018
|
|
| Merger with |
|
|
$34.9 million
November 2017
|
|
| License of Gevokizumab and certain associated IP to |
|
|
$31 million upfront
August 2017
|
|
| Acquisition of phase III royalty interest |
|
|
Undisclosed
May 2017
|
|
|
| Sale of royalties to |
|
|
$22 million
December 2016
|
|
| Sale of royalties to |
|
|
|
$17.5 million
December 2016
|
|
| Partial sale of royalty and milestones |
|
|
|
$40 million
September 2016
|
|
| Partial royalty and milestone sale to |
|
|
|
$6 million
August 2016
|
|
| Sale of phase II enzyme replacement royalty |
|
|
|
Undisclosed
August 2016
|
|
| Sale of majority stake to |
|
|
Undisclosed
July 2016
|
|
|
| Royalty-backed acquisition financing for undisclosed spec pharma |
|
|
|
$100 million
February 2016
|
|
| Senior term loan |
|
|
|
$15 million
December 2015
|
|
|
| Sale of biologics manufacturing facilities to |
|
|
$5 million in cash +
$1 million in stock November 2015
|
|
| Debt financing from |
|
|
|
$20 million
September 2015
|
|
| Acquisition financing from |
|
|
|
$20 million
October 2014
|
|
| Synthetic royalty financing from |
|
|
|
$10 million
October 2014
|
|
| Loan from |
|
|
|
$25 million
July 2014
|
|
| Financial advisor on follow-on offering |
|
|
|
$72.5 million
February 2014
|
|
| Merger into |
|
|
Undisclosed
September 2013
|
|
| Sale for up to $106 million to |
|
|
$12 million +
milestones January 2013
|
|
| Sale of Amicar® rights to |
|
|
Undisclosed
August 2012
|
|
|
| Sale of Roxicodone® to |
|
|
Undisclosed
August 2012
|
|
|
| Sale of Zipsor® to |
|
|
Undisclosed
June 2012
|
|
| Structured debt transaction linked to three pharma royalties |
|
|
$65 million
December 2011
|
|
| Financial advisor in follow-on financing for GI company |
|
|
|
Undisclosed
July 2011
|
|
| Sale of Canadian biotechnology company to |
|
|
Undisclosed
May 2011
|
|
|
| Co-promotion for Zipsor® |
|
|
Undisclosed
May 2011
|
|
|
| Sale of royalties for Cubicin® and Lexiscan® to |
|
|
$487 million
April 2011
|
|
| Acquisition of |
|
|
$40 million +
milestones June 2010
|